Ocugen (NASDAQ:OCGN) Trading Down 6.3% – Time to Sell?

Posted by Brian Himes on Jun 30th, 2026

Ocugen, Inc. (NASDAQ:OCGN – Get Free Report) traded down 6.3% on Tuesday . The company traded as low as $1.56 and last traded at $1.5650. 4,432,320 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 7,871,269 shares. The stock had previously closed at $1.67.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on OCGN. Canaccord Genuity Group reduced their price objective on Ocugen from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Weiss Ratings lowered Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Wall Street Zen raised Ocugen from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Chardan Capital reiterated a “buy” rating and set a $7.00 price target on shares of Ocugen in a report on Wednesday, March 25th. Finally, Oppenheimer began coverage on Ocugen in a research note on Wednesday, March 11th. They issued an “outperform” rating and a $10.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Get Our Latest Stock Report on OCGN

Ocugen Price Performance

The stock has a 50 day moving average of $1.43 and a two-hundred day moving average of $1.59. The company has a debt-to-equity ratio of 4.17, a quick ratio of 1.86 and a current ratio of 1.86. The firm has a market capitalization of $529.78 million, a P/E ratio of -6.52 and a beta of 2.20.

Ocugen (NASDAQ:OCGN – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Ocugen had a negative return on equity of 127,987.80% and a negative net margin of 1,192.18%.The company had revenue of $1.53 million for the quarter, compared to the consensus estimate of $0.42 million. Sell-side analysts predict that Ocugen, Inc. will post -0.22 earnings per share for the current fiscal year.

Insider Transactions at Ocugen

In other Ocugen news, CFO Treerita Essali Johnson-Greene purchased 21,000 shares of the stock in a transaction dated Monday, June 15th. The shares were bought at an average cost of $1.23 per share, with a total value of $25,830.00. Following the completion of the transaction, the chief financial officer owned 521,000 shares in the company, valued at $640,830. This trade represents a 4.20% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.95% of the stock is owned by company insiders.

Institutional Trading of Ocugen

Several hedge funds have recently added to or reduced their stakes in OCGN. Creative Planning acquired a new stake in Ocugen in the 2nd quarter valued at approximately $57,000. XTX Topco Ltd acquired a new position in shares of Ocugen during the second quarter worth approximately $203,000. Jump Financial LLC bought a new stake in shares of Ocugen in the second quarter valued at approximately $57,000. Qube Research & Technologies Ltd bought a new stake in shares of Ocugen in the second quarter valued at approximately $188,000. Finally, NewEdge Advisors LLC grew its stake in shares of Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock worth $36,000 after acquiring an additional 24,460 shares during the last quarter. Institutional investors own 10.27% of the company’s stock.

Ocugen Company Profile

(Get Free Report)

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.